Press Releases - Neurology

Press Releases - Neurology

Company’s ultra-sensitive platform continues to facilitate important advances that harness biomarkers to identify, monitor and validate treatment pathways for Multiple Sclerosis (MS) | September 10, 2020
September 10, 2020 09:00 AM Eastern Daylight Time
July 27, 2020
Company’s ultra-sensitive Simoa® technology powers more than 50 posters and presentations on display during this year’s virtual program; attendees can be among the first to experience Simoa p-tau181 assay for improved study of Alzheimer’s disease and visit virtual exhibitor booth
May 29, 2020
Preliminary research demonstrates the biomarker’s revolutionary potential to empower accessible and scalable blood testing for Alzheimer’s disease; Quanterix to discuss latest findings and how researchers can gain early access to newest Simoa assay during June 3 PPH we
January 31, 2020
New CARE Consortium study, representing the largest biomarker study on sports-related concussions (SRC) applies ultra-sensitive biomarker solution to validate serum markers as objective indicators of mild traumatic brain injury (mTBI)
Continued growth in 2019 marked by new HD-X product launch, acquisition of the leading neurofilament light (Nf-L) antibody supplier, new corporate headquarters and new ground-breaking neurodegenerative research proving the utility of digital biomarkers ac | July 11, 2019
BILLERICA, Mass.--(BUSINESS WIRE)--

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more